Evidence map›Paper›PMID 9013471›Full record

Trial reportMedical oncology (Northwood, London, England)1996

Phase II trial of docetaxel (Taxotere) in patients with adenocarcinoma of the upper gastrointestinal tract previously untreated with cytotoxic chemotherapy: the Eastern Cooperative Oncology Group (ECOG) results of protocol E1293.

A I Einzig, D Neuberg, S C Remick, D D Karp, P J O'Dwyer, J A Stewart, A B Benson

3 registry-linked trialsAbstract readClinical TrialClinical Trial, Phase II
PubMed Publisher
In one paragraph

Trial report in Medical oncology (Northwood, London, England), 1996. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 3 registered trials, which are not on this map. Cited by 59 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
59citing papers in PubMed, 1 pooled it
1.0field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01187212 phase2completednot on this mapstarted 2010, after this paper: background citation

A Randomized Phase II Study of Capecitabine and Cisplatin (XP) +/- Sorafenib (Nexavar®) in Patients With Advanced Gastric Cancer

TypeinterventionalSponsorAsan Medical CenterRan2010 to 2014Enrolled195ConditionsMalignant Neoplasm of Stomach, Effects of ChemotherapyArmsCapecitabine/Cisplatin + Sorafenib, Capecitabine/Cisplatin
NCT02969473 phase2unknown statusnot on this mapstarted 2010, after this paper: background citation

Definitive Concurrent Chemoradiotherapy With Docetaxel Plus Cisplatin Versus 5-fluorouracil Plus Cisplatin in Patients With Esophageal Squamous Cell Carcinoma: a Phase II Randomized Controlled Trial

TypeinterventionalSponsorZhu YujiaRan2010 to 2017Enrolled120ConditionsEsophageal Neoplasm, ChemoradiationArmsDocetaxel, Fluorouracil
NCT07126561 phase2not yet recruitingnot on this mapstarted 2026, after this paper: background citation

Phase II Open Label Trial of Trastuzumab Deruxtecan (Enhertu, DS-8210) in HER2 Positive Newly Diagnosed Metastatic Esophageal, Gastric, GEJ Cancer Patients With an ECOG Performance Status of 2

TypeinterventionalSponsorUniversity of ChicagoRan2026 to 2028Enrolled43ConditionsHER2 Positive Newly Diagnosed Metastatic Esophageal, Gastric, GEJ Cancer Patients With an ECOG Performance Status of 2ArmsTrastuzumab Deruxtecan
3 · Its place in the literature

Who cites it

59 citing papers in PubMed, 1 synthesis or guideline pooled it, 196 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Trial
  4. Trial
  5. Sequential chemotherapy with cisplatin, leucovorin, and 5-fluorouracil followed by docetaxel in previously untreated patients with metastatic gastric cancer: a phase II study.Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association · 2012
    Trial
  6. Trial
  7. Randomized phase II study of sequential docetaxel and irinotecan with 5-fluorouracil/folinic acid (leucovorin) in patients with advanced gastric cancer: the GATAC trial.Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association · 2010
    Trial
  8. Trial
  9. Trial
  10. Trial
  11. Trial
  12. Trial
  13. Phase II multicenter trial of docetaxel, epirubicin, and 5-fluorouracil (DEF) in the treatment of advanced gastric cancer: a novel, safe, and active regimen.Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association · 2006
    Trial
  14. Trial
  15. Trial
  16. Trial
  17. Trial
  18. Trial
  19. Trial
  20. Docetaxel and cisplatin in patients with advanced gastric cancer: results of Japanese phase I/II study.Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association · 2002
    Trial
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 7 institutions in 1 country.

A I EinzigAlbert Einstein Cancer Center, Bronx, New York 10461, USA.
D Neuberg
S C Remick
D D Karp
P J O'Dwyer
J A Stewart
A B Benson
Albany Medical Center Hospital · USDana-Farber Cancer Institute · USFox Chase Cancer Center · USNorthwestern University · USTufts Medical Center · USUniversity of Wisconsin–Madison · USYeshiva University · US

Funding

PROVIDE STATISTICAL SERVICESU10CA023318 · NCI · DANA-FARBER CANCER INSTITUTE · PI GRAY, ROBERT J · 1985 to 2013
$33.4M
ONCOLOGYU10CA014958 · NCI · YESHIVA UNIVERSITY · PI SPARANO, JOSEPH A. · 1985 to 2013
$2.2M
EASTERN COOPERATIVE ONCOLOGY GROUPU10CA006594 · NCI · ALBANY MEDICAL COLLEGE · PI REMICK, SCOT C · 1985 to 1994
–
NCI NIH HHS CA06594NCI NIH HHS CA14958NCI NIH HHS CA23318
6 · The paper itself

Abstract

The aim of this study was to evaluate the clinical efficacy and safety of docetaxel (Taxotere) in patients with adenocarcinoma of the upper gastrointestinal tract previously untreated with cytotoxic chemotherapy. Docetaxel 100 mg m-2 was administered as a 1 hour intravenous (IV) infusion every 3 weeks to 41 patients. Patients were premedicated prior to each course with dexamethasone, diphenhydramine and cimetidine. Clinical response and toxicity were determined. Objective responses were seen in seven of 41 eligible patients (two complete responses [CRs] and five partial responses [PRs], for an objective response rate of 17% (90% confidence interval [CI], 8% to 30%). The most common toxicity was grade 4 neutropenia, which occurred in 88% of patients; 46% of patients required a dose reduction following an episode of neutropenic fever requiring antibiotic therapy. Additional patients have had reversible grade 3-4 toxicities including nausea, vomiting, stomatitis, diarrhea, fatigue and peripheral neuropathy. Ten patients have had grade 1-3 hypersensitivity reactions. Alopecia has been seen in the majority of patients. Fluid retention grade 1-3 has been observed in patients. Docetaxel administered on this schedule is an active agent in adenocarcinomas of the upper gastrointestinal tract. Further investigation of this drug should be conducted in multi-drug combination programs.

Indexed as

TaxoidsAdenocarcinomaAdultAgedAntineoplastic Agents, PhytogenicDisease-Free SurvivalDocetaxelEsophageal NeoplasmsFemaleHumansMaleMiddle AgedPaclitaxelRemission InductionStomach NeoplasmsSurvival RateAntineoplastic Agents, PhytogenicDocetaxelPaclitaxelTaxoids

Identifiers

PMID9013471
OpenAlexW1992103975

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.